We are excited to announce that Biocytogen will attend UK Biotech Day from May 27th - 28th. This international conference serves as a premier networking event showcasing UK life science innovation. Join us in discussing the latest strategies and emerging trends that are shaping the future of biotech.
What is UK Biotech Day?
UK Biotech Day unites key industry leaders from across the biotech ecosystem for two full days of learning and collaboration. This year’s program will cover R&D, BD&L, clinical development, regulatory affairs, market access, and more. Don’t miss out on this opportunity to connect and form meaningful partnerships.
Event Overview
Date: May 27th - 28th, 2026
Venue: Radisson Hotel & Conference Centre London Heathrow, Building A, Bath Rd, Heathrow Blvd, Sipson, West Drayton UB7 0DU, United Kingdom
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in London, UK!
